Literature DB >> 19082994

Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?

Alexander Jetter1, Martina Kinzig, Michael Rodamer, Dorota Tomalik-Scharte, Fritz Sörgel, Uwe Fuhr.   

Abstract

OBJECTIVES: Individual activities of N-acetyltransferase 2 (NAT2) and of xanthine oxidase (XO) can be assessed using ratios of urinary caffeine metabolites. We investigated how ratios changed over time and which urine collection interval would be the best for NAT2 and XO activity assessments.
METHODS: On two occasions separated by 14 days, 16 healthy male Caucasians collected urine before and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16 and 16-24 h after a dose of 150 mg caffeine given in the framework of a phenotyping cocktail study. The metabolites 5-acetylamino-6-formylamino-3-methyluracil (AFMU), 5-acetylamino-6-amino-3-methyluracil (AAMU), 1-methylxanthine (1X), and 1-methylurate (1U) were quantified with LC-MS/MS. The molar ratio (AFMU + AAMU)/(1X + 1U + AFMU + AAMU) was used as a NAT2 metric, while the ratio 1U/(1X + 1U) served as XO metric.
RESULTS: The NAT2 ratios were stable in the intervals 4-24 h after caffeine dosing. Mean intra-individual coefficients of variation were 11-23% starting 4 h post-dose, while inter-individual variability reached 37-75%. The XO ratios increased gradually by 14% from the 2-4 to the 16-24 h interval. The mean intra- and inter-individual coefficients of variation of XO activity were 3-18 and 7-10% respectively. No significant differences between study occasions were observed.
CONCLUSIONS: Any sampling interval at least 4 h after caffeine dosing is suitable for NAT2 and XO activity assessments. XO activities can only be compared between volunteers and studies if the same urine collection schedule has been respected. The low intraindividual variability allows for sample sizes of 16 and 6 participants in crossover interaction studies of NAT2 and XO activity respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19082994     DOI: 10.1007/s00228-008-0597-0

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Sample size determination for bioequivalence assessment by means of confidence intervals.

Authors:  E Diletti; D Hauschke; V W Steinijans
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-01

Review 2.  Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Authors:  Pál Pacher; Alex Nivorozhkin; Csaba Szabó
Journal:  Pharmacol Rev       Date:  2006-03       Impact factor: 25.468

3.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

4.  Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.

Authors:  Fatima Vrtic; Walter E Haefeli; Jürgen Drewe; Stephan Krähenbühl; Markus Wenk
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

5.  Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.

Authors:  P Fuchs; W E Haefeli; H R Ledermann; M Wenk
Journal:  Eur J Clin Pharmacol       Date:  1999-01       Impact factor: 2.953

6.  NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios.

Authors:  A Nyéki; T Buclin; J Biollaz; L A Decosterd
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

7.  Xanthine oxidase activity is influenced by environmental factors in Ethiopians.

Authors:  Eleni Aklillu; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2003-08-21       Impact factor: 2.953

8.  Polymorphic N-acetylation of a caffeine metabolite.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

9.  Effect of allopurinol on caffeine disposition in man.

Authors:  D M Grant; B K Tang; M E Campbell; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

10.  Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".

Authors:  Siwaporn Chainuvati; Anne N Nafziger; J Steven Leeder; Andrea Gaedigk; Gregory L Kearns; Edward Sellers; Yanhua Zhang; Angela D M Kashuba; Elizabeth Rowland; Joseph S Bertino
Journal:  Clin Pharmacol Ther       Date:  2003-11       Impact factor: 6.875

View more
  6 in total

1.  In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population.

Authors:  Natasa Djordjevic; Juan Antonio Carrillo; Guillermo Gervasini; Slobodan Jankovic; Eleni Aklillu
Journal:  Eur J Clin Pharmacol       Date:  2010-02-13       Impact factor: 2.953

2.  Caffeine, Paraxanthine, Theophylline, and Theobromine Content in Human Milk.

Authors:  Aleksandra Purkiewicz; Renata Pietrzak-Fiećko; Fritz Sörgel; Martina Kinzig
Journal:  Nutrients       Date:  2022-05-25       Impact factor: 6.706

3.  Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate.

Authors:  Peter E Haroldsen; Marvin R Garovoy; Donald G Musson; Huiyu Zhou; Laurie Tsuruda; Boyd Hanson; Charles A O'Neill
Journal:  Pharmacol Res Perspect       Date:  2014-12-09

4.  Determination of Urinary Caffeine Metabolites as Biomarkers for Drug Metabolic Enzyme Activities.

Authors:  Hyeong Jun Kim; Min Sun Choi; Shaheed Ur Rehman; Young Seok Ji; Jun Sang Yu; Katsunori Nakamura; Hye Hyun Yoo
Journal:  Nutrients       Date:  2019-08-19       Impact factor: 5.717

5.  Improved genotyping of N-acetyltransferase 2: role of the ultra-slow acetylators.

Authors:  Meinolf Blaszkewicz
Journal:  EXCLI J       Date:  2013-12-05       Impact factor: 4.068

6.  Serum Metabolite Biomarkers Discriminate Healthy Smokers from COPD Smokers.

Authors:  Qiuying Chen; Ruba S Deeb; Yuliang Ma; Michelle R Staudt; Ronald G Crystal; Steven S Gross
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.